Citi kept its Buy rating and raised its price goal to $800, supporting a more favorable view of Thermo Fisher. The story gives no new company results, so the support comes only from Citi's assessment.
That is a more favorable view of Thermo Fisher's prospects, but it comes from one analyst, not new company results. The story gives no sales or profit update, so the support is limited to Citi's assessment.
Follow Thermo Fisher Scientific (TMO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TMO